Wall Street analyst estimates for Cerus Corporation (CERS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.01 | ||
| 2026-07-30 | $-0.01 | $-0.01 | +25.0% |
| 2026-04-30 | $-0.01 | $-0.03 | +66.7% |
| 2026-03-02 | $-0.01 | $-0.01 | +0.0% |
| 2025-11-06 | $-0.00 | $-0.02 | +99.5% |
| 2025-08-05 | $-0.03 | $-0.02 | -50.0% |
| 2025-05-01 | $-0.04 | $-0.05 | +20.0% |
| 2025-02-20 | $-0.01 | $-0.01 | +0.0% |
Valuation Ratios
| Price / Book | 6.88 |
| EV / EBITDA | 192.78 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.2M | $43.6M | $60.9M | $74.6M | $91.9M | $130.9M | $162.0M | $156.4M | $180.3M | $206.1M |
| Cost of Revenue | $20.3M | $22.5M | $31.6M | $33.4M | $41.2M | $63.5M | $75.0M | $70.0M | $80.7M | $93.8M |
| Gross Profit | $16.9M | $21.0M | $29.3M | $41.2M | $50.8M | $67.4M | $87.1M | $86.4M | $99.5M | $112.3M |
| Research & Development | $31.3M | $33.7M | $42.6M | $60.4M | $64.4M | $63.7M | $64.1M | $67.6M | $58.9M | $67.7M |
| Selling, General & Admin | $48.8M | $52.4M | $56.8M | $66.2M | $67.0M | $81.3M | $83.3M | $75.5M | $75.9M | $80.9M |
| Operating Expenses | $78.2M | $78.6M | $84.3M | $107.5M | $109.1M | $116.3M | $121.2M | $116.5M | $113.7M | $121.0M |
| Operating Income | -$61.4M | -$57.5M | -$55.0M | -$66.2M | -$58.3M | -$48.9M | -$34.1M | -$30.1M | -$14.2M | -$8.7M |
| EBITDA | -$58.5M | -$51.9M | -$51.9M | -$64.6M | -$51.4M | -$46.0M | -$33.5M | -$26.3M | -$10.0M | -$5.5M |
| Interest Expense | $2.4M | $3.0M | $4.0M | $6.1M | $3.7M | $4.9M | $5.8M | $8.4M | $8.9M | $8.3M |
| Pre-tax Income | -$62.7M | -$56.7M | -$57.3M | -$71.0M | -$59.6M | -$54.1M | -$42.3M | -$37.3M | -$20.8M | -$15.3M |
| Income Tax | $175000 | $3.9M | $229000 | $263000 | $284000 | $319000 | $488000 | $325000 | $205000 | $354000 |
| Net Income | -$62.9M | -$60.6M | -$57.6M | -$71.2M | -$59.9M | -$54.4M | -$42.8M | -$37.5M | -$20.9M | -$15.6M |
| EPS | $-0.62 | $-0.56 | $-0.44 | $-0.51 | $-0.37 | $-0.32 | $-0.24 | $-0.21 | $-0.11 | $-0.08 |
| EPS (Diluted) | $-0.62 | $-0.56 | $-0.44 | $-0.51 | $-0.37 | $-0.32 | $-0.24 | $-0.21 | $-0.11 | $-0.08 |
| Shares Outstanding (Diluted) | $101.8M | $108.2M | $131.7M | $139.8M | $163.9M | $171.3M | $176.5M | $180.3M | $184.6M | $190.6M |
Price
| Price | $2.53 |
| Market Cap | $510M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CVRX · MASS · NPCE · QTRX · RXST · SENS · SGHT
Explore sector: Healthcare · Medical - Devices
More sections of CERS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks